Project Grant R56DA066990
Award Date 8/15/26
Completion Date 7/31/27
Dollars Obligated $909K
Funding Federal Agency
Awarding Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Chapel Hill, NC 27599, USA
Similar Awards
- The National Institutes of Health Office of the Director awarded Beth Israel Deaconess Medical Center $508,734 on August 15, 2026, under the Trans-NIH Research Support program (CFDA 93.310) to investigate the neural mechanisms underlying fentanyl-xylazine overdose lethality and identify therapeutic reversal strategies. The award funds research into how fentanyl and xylazine—a veterinary sedative increasingly found as an adulterant in illicit opioid supplies—synergistically inhibit lateral...
- The National Institute on Drug Abuse awarded the Regents of the University of Minnesota $423,500 on June 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to investigate the neuropharmacology of xylazine and fentanyl interactions. The recipient will characterize the pharmacological mechanisms of xylazine alone and in combination with fentanyl using preclinical models of analgesia, sedation, opioid tolerance, opioid withdrawal, and opioid self-administration in mice. The...
- This Project Grant award for $423,708 was provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279). The funding will support research to investigate the effects of fentanyl-xylazine drug mixtures on cardiorespiratory function and subjective effects in rats. Specifically, the research aims to characterize how xylazine impacts fentanyl-induced changes in heart rate, blood pressure, temperature, and respiration, as well as determine if...
- The National Institute on Drug Abuse awarded the University of Pittsburgh $434,005 on May 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to investigate xylazine's mechanisms of action on human cell receptors and identify natural product compounds that can reverse xylazine-induced damage. The research addresses a critical gap in understanding xylazine's pharmacological effects beyond its known action on alpha-2 adrenergic receptors. Current FDA-approved medications,...
- The National Institute on Drug Abuse awarded Thomas Jefferson University $693,000 on February 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct research on xylazine exposure among pregnant women who use opioids and to generate evidence-based approaches to treatment for this population. The research addresses the rapid spread of xylazine across the United States, with xylazine-positive overdoses increasing over 1,000 percent in the South and 750 percent in...
- The National Institutes of Health Office of the Director awarded the University of California, San Diego $480,000 on August 15, 2026, under the Trans-NIH Research Support program (CFDA 93.310) to conduct research on metabolic-epigenetic mechanisms of neurotoxicity following acute fentanyl exposure. The project, which runs through June 30, 2031, investigates how ultra-potent synthetic opioids such as fentanyl cause delayed neurological consequences in overdose survivors despite effective opioid...
- The National Institute on Drug Abuse awarded The Washington University $1,155,062 on March 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to generate multiomics data characterizing cellular mechanisms underlying fentanyl-induced respiratory depression in opioid overdose decedents. The award funds single-nucleus RNA-seq and ATAC-seq (snRNAseq and snATACseq) paired multiomics analysis of brainstem respiratory control regions—the prebotzinger complex and ventral...
- The National Institute on Drug Abuse awarded Arizona State University $1,546,664 on August 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a four-year study characterizing xylazine-adulterated illicitly manufactured fentanyl use and xylazine test strip acceptance in the southwestern United States. The research integrates mixed-methods data collection on xylazine-related knowledge, experiences, and risks with urine toxicology analyses using onsite and...
- The National Institutes of Health Office of the Director awarded the University of Miami a project grant of $460,500 on August 15, 2026, under the Trans-NIH Research Support program (CFDA 93.310) to investigate microbiome-mediated persistent neuroimmune injury following single fentanyl exposure. The research examines how ultra-potent synthetic opioids such as fentanyl induce delayed biological injury in survivors of sub-lethal exposure, with focus on mechanisms underlying impaired cognition...
- The National Institute on Drug Abuse awarded the University of California, San Diego $138,522 under the Drug Use and Addiction Research Programs (CFDA 93.279) on January 21, 2026. The award funds research evaluating the multiscale effects of fentanyl-induced dependence and abstinence within the mouse basolateral amygdala. The research employs virally-mediated strategies, nuclear labeling, and single-nucleus RNA sequencing to assess how fentanyl dependence and abstinence differentially affect...